Evaluating Bronchoscopic Airway Clearance and Amphotericin B Spraying alongside Standard Treatment in Adults with Allergic Bronchopulmonary Aspergillosis

What this Trial Is About

Researchers are evaluating the efficacy and safety of bronchoscopic airway clearance combined with amphotericin B spraying for patients with allergic bronchopulmonary aspergillosis ABPA. This study compares this procedure along with standard drug therapy against standard therapy alone, aiming to improve treatment outcomes such as symptom remission and immunological response. The study is observational and involves patients diagnosed with active ABPA, including newly diagnosed cases or acute exacerbations. Participants in the observation group will receive standard drug treatment, which includes oral glucocorticoids with or without oral antifungal drugs, along with bronchoscopic airway clearance and amphotericin B spraying. The control group will receive only the standard drug therapy while maintaining previous asthma treatments like inhaled corticosteroids and long-acting beta-agonists. The bronchoscopic procedure is performed based on mucus plug removal effectiveness and is given at least once. Both groups continue their usual asthma medications. Participants will be monitored for radiographic response, immunological remission, and clinical symptom remission after 4 months of treatment. Additional outcomes include acute exacerbations, hospitalizations, quality of life, immunological markers, psychological assessments, and mortality tracked up to 2 years. The study includes imaging, blood tests, and symptom evaluations to assess treatment effects and safety over time. The total participation period includes treatment and long-term follow-up for comprehensive outcome measurement.

A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA